Skip to main content

Repotrectinib Approved for ROS1-Positive Non–Small Cell Lung Cancer

The FDA has approved repotrectinib (Augtyro™, Bristol Myers Squibb Company) for locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). This is the first approval for the next-generation ROS1/TRK tyrosine kinase inhibitor (TKI) repotrectinib and is the first FDA approval to include patients with ROS1-positive NSCLC who have previously received a ROS1 TKI, as well as patients who are TKI-naive.   Why it matters: "Repotrectinib is a next-generation ROS1 and TRK TKI th...

Continue reading